News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
News Merck partners Remepy in PDURS-focused alliance Merck KGaA has started working with Remepy on the development of hybrid drugs that combine medicines with digital therapeutics.
Digital Health Innovators – Or Shoval and Shahar Shelly Why do the same medications work well in some patients and poorly in others? One reason might be the poorly understood connection between mind and body.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.